Last reviewed · How we verify
Ropivacaine 0.2% for LFCB
Ropivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and propagation of action potentials.
Ropivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and propagation of action potentials. Used for Local infiltration anesthesia, Regional anesthesia (nerve blocks, epidural, peripheral nerve blocks).
At a glance
| Generic name | Ropivacaine 0.2% for LFCB |
|---|---|
| Sponsor | Poznan University of Medical Sciences |
| Drug class | Local anesthetic (amide) |
| Target | Voltage-gated sodium channels |
| Modality | Small molecule |
| Therapeutic area | Anesthesia |
| Phase | FDA-approved |
Mechanism of action
Ropivacaine is an amide-type local anesthetic that reversibly inhibits sodium influx through voltage-gated sodium channels in nerve fibers, thereby preventing depolarization and nerve impulse transmission. This results in local loss of sensation in the area where it is administered. The 0.2% concentration is a dilute formulation suitable for infiltration and regional anesthesia techniques.
Approved indications
- Local infiltration anesthesia
- Regional anesthesia (nerve blocks, epidural, peripheral nerve blocks)
Common side effects
- Injection site reactions (pain, erythema)
- Systemic toxicity (CNS effects: dizziness, tinnitus, seizures)
- Cardiovascular effects (hypotension, bradycardia, arrhythmias)
- Allergic reactions
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ropivacaine 0.2% for LFCB CI brief — competitive landscape report
- Ropivacaine 0.2% for LFCB updates RSS · CI watch RSS
- Poznan University of Medical Sciences portfolio CI